Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyloNerv-D
- Development stage
- Unknown
- Lead developer
- Precia Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MyloNerv-D is a branded generic oral formulation and nutraceutical developed by Precia Pharma Private Limited for the management of neuropathy, including diabetic and peripheral neuropathy. The product is a combination tablet containing alpha-lipoic acid (200 mg), methylcobalamin (1500 mcg), pyridoxine hydrochloride (3 mg), folic acid (1.5 mg), biotin (200 mcg), and vitamin D3 (1000 IU). Alpha-lipoic acid acts as a potent antioxidant that mitigates oxidative stress and supports cellular energy production, while the B-vitamins (B6, B9, B12) and biotin work synergistically to support nerve regeneration, maintain myelin sheath integrity, and reduce homocysteine levels. Vitamin D3 is included to support overall neurological and bone health. It is marketed in India as an approved product for managing vitamin deficiencies and supporting neurological health.
- Brand names
- MyloNerv-D
- Other names
- Alpha-Lipoic Acid 200 mg
02
Targets
MTR (Methionine synthase)PDH (Pyruvate dehydrogenase complex)
Beyond the preview
Go deeper on MyloNerv-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyloNerv-D.